Lineage Cell Therapeutics, Inc. Common Stock
Key Metrics
Market Snapshot
About
Lineage Cell Therapeutics Inc (LCTX) is a clinical-stage biotechnology company based in Carlsbad, California, best known for developing cell replacement therapies designed to address serious conditions including vision loss, spinal cord injury, and hearing loss.
The company's primary product candidates are derived from its cell differentiation technology platform. Its lead program, OpRegen, is an allogeneic retinal pigment epithelium cell therapy currently in a Phase 2a clinical trial for geographic atrophy secondary to age-related macular degeneration. Another key candidate, OPC1, is an allogeneic oligodendrocyte progenitor cell therapy in a Phase 1/2a clinical trial for the treatment of cervical spinal cord injuries.
Lineage's pipeline includes several other preclinical-stage cell transplant programs. These include ReSonance for sensorineural hearing loss and PNC1 for vision loss due to photoreceptor damage. The company is also developing novel cell lines, including a hypoimmune induced pluripotent stem cell line, for future therapeutic candidates targeting areas like Type 1 diabetes and oncology. To advance its research, Lineage has established strategic collaborations, such as an agreement with William Demant Invest for its hearing loss program and a partnership with Factor Bioscience Inc. for genetically engineered cell lines. Formerly known as BioTime, Inc., the company was incorporated in 1990 and rebranded to Lineage Cell Therapeutics in August 2019.